Genomic Valley Biotech Ltd (539206)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 30 அக். 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 14 ஆக. 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Genomic Valley Biotech Ltd reported Q2 FY27 results on 30 Oct 2026: revenue ₹0.0 Cr (-100.0% year on year, -100.0% on the previous quarter), and net profit ₹-0.0 Cr.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY Q2 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹0.0 | -100.0% | -100.0% |
| செயல்பாட்டு லாபம் | ₹-0.0 | — | நஷ்டமாக |
| நிகர லாபம் | ₹-0.0 | — | நஷ்டமாக |
| EPS (₹) | -0.06 | — | நஷ்டமாக |
- லாபம் இருந்தும் FY26-இல் செயல்பாட்டுப் பணப்புழக்கம் எதிர்மறையாக இருந்தது
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Acquirers Pankaj Grover and Abhisek Gupta have filed a Draft Letter of Offer to acquire up to 7,94,170 equity shares (26% voting share capital) of Genomic Valley Biotech Ltd. The open offer is priced at ₹30 per share in cash, triggered by a Share Purchase Agreement dated October 19, 2026. The total open offer consideration stands at approximately ₹2.38 crore, compared to the company's current market cap of ₹9 crore. An escrow cash deposit of ₹60 lakh has been confirmed with YES Bank.
- Open offer to acquire up to 7,94,170 equity shares, representing 26% of total voting capital
- Offer price fixed at ₹30 per share payable in cash, close to current trading price of ₹29.9
- Triggered by a Share Purchase Agreement entered on October 19, 2026 with the promoter seller
- Tentative tendering period scheduled from December 14, 2026 to December 28, 2026
- Cash deposit of ₹60,00,000 confirmed in escrow account with YES Bank Limited
Genomic Valley Biotech approved its unaudited standalone financial results for the quarter and half-year ended September 30, 2026. The statutory auditor, ANDROS & CO., issued an unmodified limited review report with no audit qualifications. Specific financial figures such as revenue, EBITDA, and PAT were not detailed in the visible report excerpt. The micro-cap company currently holds a market cap of approximately Rs 9 crore with negligible TTM revenues.
- Board approved standalone unaudited results for quarter and half year ended September 30, 2026
- Meeting commenced at 05:15 P.M. and concluded at 05:45 P.M. on October 30, 2026
- Limited review report issued by statutory auditor ANDROS & CO. with an unmodified conclusion
Genomic Valley Biotech has released its Detailed Public Statement for an open offer to acquire up to 7,94,170 equity shares under SEBI SAST Regulations. The offer is being made by Pankaj Grover and Abhisek Gupta through manager Fintellectual Corporate Advisors. This indicates a potential change in control or substantial acquisition in the microcap biotech firm, which currently has a market cap of approximately Rs 9 Cr.
- Open offer for acquisition of up to 7,94,170 equity shares from public shareholders
- Acquisition initiated by Mr. Pankaj Grover (Acquirer 1) and Mr. Abhisek Gupta (Acquirer 2)
- Fintellectual Corporate Advisors Private Limited appointed as the Manager to the Open Offer
- Detailed Public Statement published on October 27, 2026 across English, Hindi, and Marathi newspapers
Promoter Yogesh Agrawal has entered into a Share Purchase Agreement (SPA) on October 19, 2026, to sell his entire stake of 14,07,000 equity shares (46.06% voting capital) to Mr. Pankaj Grover and Mr. Abhisek Gupta. The proposed transaction will result in a complete change of control and reclassification of the acquirers as promoters. As a consequence, an open offer will be triggered under SEBI (SAST) Regulations for public shareholders. Following the transaction, existing promoter directors will resign from the board.
- Promoter Yogesh Agrawal selling 100% of his holding of 14,07,000 equity shares
- Stake represents 46.06% of the company's total voting share capital
- Share Purchase Agreement executed on October 19, 2026
- Acquisition triggers a mandatory Open Offer to public shareholders under SEBI (SAST) Regulations
- Existing promoter directors will tender their resignation from the board upon completion
Genomic Valley Biotech Limited has received approval from the Registrar of Companies (ROC), Haryana, granting a 3-month extension to conduct its Annual General Meeting (AGM) for the financial year ended March 31, 2026. The AGM, which was originally due on or before September 30, 2026, can now be held up to December 31, 2026. The extension was sought citing health reasons of the promoter. The company noted that the exact date of the AGM will be intimated in due course once decided by the Board.
- ROC Haryana approved a 3-month extension for holding the FY26 AGM via letter dated August 30, 2026
- AGM deadline extended from September 30, 2026, up to December 31, 2026
- Application was filed under Section 96(1) of the Companies Act, 2013 on August 26, 2026, citing promoter health reasons
- Board will intimate the revised AGM schedule and book closure dates in due course
Genomic Valley Biotech approved its standalone unaudited financial results for the quarter ended June 30, 2026. The company registered revenue of ₹0.038 crore, down from ₹0.09 crore in the corresponding quarter of the previous year. Net profit stood at ₹0.015 crore (EPS of ₹0.05), recovering from a net loss of ₹0.01 crore in the previous quarter (Q4 FY26). The statutory auditors issued an unmodified limited review report.
- Standalone quarterly revenue reported at ₹0.038 crore for the quarter ended June 30, 2026.
- Net profit recorded at ₹0.0146 crore with an EPS of ₹0.05.
- Board meeting concluded in 40 minutes (03:00 PM to 03:40 PM on August 14, 2026).
- Statutory auditor ANDROS & CO issued a clean/unmodified Limited Review Report.
Genomic Valley Biotech Ltd has approved its standalone un-audited financial results for the quarter ended June 30, 2026. The company is a micro-cap with a market capitalization of only ‑8 Cr and has seen a significant decline in annual revenue from ‑0.84 Cr in FY25 to ‑0.27 Cr in FY26. Recent quarterly performance shows revenue stagnating between ‑0.04 Cr and ‑0.09 Cr. The board meeting was brief, lasting 40 minutes, and the statutory auditors provided a standard limited review report without qualifications.
- Board approved standalone un-audited financial results for the quarter ended June 30, 2026
- Company revenue has declined significantly from ‑0.84 Cr in FY25 to ‑0.27 Cr in FY26
- Market capitalization remains extremely low at ‑8 Cr with a high P/E ratio of 414.4
- The board meeting commenced at 03:00 P.M. and concluded at 03:40 P.M. on August 14, 2026
- Promoter holding has remained stable at 46.06% as of June 2026
Genomic Valley Biotech Ltd (Market Cap: Rs 8 Cr) has scheduled a board meeting for August 14, 2026, to approve its unaudited standalone results for the quarter ended June 30, 2026. The company is currently operating on a very small scale, with FY26 revenue falling to Rs 0.27 Cr from Rs 0.84 Cr in FY25. The trading window for insiders has been closed since July 01, 2026, and will reopen 48 hours after the results are made public. Given the high P/E ratio of 414.3 and negligible revenue, the upcoming results are critical for assessing the company's operational viability.
- Board meeting scheduled for August 14, 2026, to consider Q1 FY27 results
- Trading window closed from July 01, 2026, until 48 hours after the results are public
- Company reported a low revenue of Rs 0.27 Cr for the full year FY26
- Market capitalization is approximately Rs 8 Cr with a high P/E of 414.3
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
